News

July 14, 2017July 14, 2017

Idelvion Shown to Benefit Both Adult and Pediatric Patients With Hemophilia B

News

The latest results of CSL Behring’s recombinant coagulation factor IX (FIX) Idelvion, also known by its generic name CSL654, demonstrated long-lasting therapeutic potential for both pediatric and adult patients ... Read more

July 12, 2017August 9, 2017

Bayer Awards $2 Million in Hemophilia Research and Patient-care Grants to 16 People

News

Bayer has awarded a combined $2 million in hemophilia research and patient-care grants to 16 scientists and doctors from eight countries. Four of the winners are from the United ... Read more

July 10, 2017

Positive Data on Eloctate and Alprolix on Long-term Joint Health, Bleeding in Hemophilia to Be Presented

News

Treatment with Eloctate and Alprolix improves joint health, bleeding episodes and quality of life of patients with hemophilia, Bioverativ and Sweden’s Sobi recently announced. The data is being presented ... Read more

July 7, 2017

Shire Asks FDA for a Designation That Will Lead to More Clinical Trials of Its Hemophilia A Therapy SHP654

News

Shire has asked the U.S. Food and Drug Administration to grant Investigational New Drug status to its hemophilia A treatment SHP654. The gene therapy helps generate a clotting protein known ... Read more

July 5, 2017

Hemophilia Organizations Oppose Senate’s Obamacare Replacement Legislation

News

Organizations championing patients with hemophilia and other bleeding disorders have formed a united front to oppose the Better Care Reconciliation Act, the Obamacare replacement legislation that the groups contend ... Read more

June 30, 2017June 30, 2017

Europe Grants Orphan Drug Status to CB 2679d to Prevent Hemophilia B Bleeding Episodes

News

European regulators have granted orphan drug status to CB 2679d, a hemophilia B therapy that Catalyst Biosciences developed to prevent bleeding episodes. The therapy, known as ISU304 in South Korea, prevents ... Read more

June 28, 2017

Emicizumab Shows Promise in Trials as Preventive Treatment in Hemophilia A for All Ages

News

Results from two Phase 3 trials support the use of emicizumab for the preventive treatment of hemophilia A in children, adolescents, and adults, Genentech announced. These results will be ... Read more

June 26, 2017June 26, 2017

Shire’s Experimental Gene Therapy Delivery Strategies Show Potential for Hemophilia A and B

News

Shire is developing a potential new strategy to improve the effectiveness of genetic delivery of clotting factor VIII (FVIII) for the treatment of patients with hemophilia A, and clotting ... Read more

June 26, 2017June 26, 2017

Spark to Update Results from Trial Assessing SPK-9001 in Hemophilia B Patients

News

Spark Therapeutics will present novel results regarding the ongoing Phase 1/2 clinical trial (NCT02484092) investigating SPK-9001 in hemophilia B patients at the International Society on Thrombosis and Haemostasis (ISTH) ... Read more

June 23, 2017June 23, 2017

Whole Body Vibration Increases Muscle Strength and Bone Mineral Density in Children with Hemophilia, Study Shows

News

A new study suggests that whole body vibration training increases muscle strength, bone mineral density, and functional capacity in children with hemophilia. The study, “Effect of whole body vibration ... Read more